Skip to main content

Table 2 Demographic data and clinical characteristics of patients with HCC

From: Hepatocellular carcinoma in nonalcoholic fatty liver disease with or without cirrhosis: a population-based study

 

HCC in non-cirrhotic NAFLD

n (%)

HCC in cirrhotic NAFLD

n (%)

P value

Total

170 (100)

940 (100)

 

Gender

  

< 0.397

 Male gender

100 (58.8)

520 (55.3)

 

 Female gender

70 (41.2)

420 (44.7)

 

Age group

  

0.008

 Age > 65 years

110 (64.7)

700 (74.5)

 

 Age 18–65 years

60 (35.3)

240 (25.5)

 

Race

  

< 0.001

 Non-Hispanic white

130 (76.4)

800 (85.1)

 

 Non-Hispanic black

20 (11.8)

20 (2.1)

 

 Hispanic

20 (11.8)

120 (12.8)

 

Comorbidities

   

 Obesity

70 (41.2)

490 (52.1)

0.009

 Morbid obesity

20 (11.8)

240 (25.5)

< 0.001

 Diabetes mellitus

100 (58.8)

700 (74.5)

< 0.001

 Hypertension

140 (82.4)

770 (81.9)

0.891

 Hyperlipidemia

130 (76.5)

590 (62.8)

0.001

Smoker

30 (17.6)

230 (24.5)

0.053

Laboratory data

   

 High ALT

110 (64.7)

600 (63.8)

0.827

Medication use

   

 Statin

100 (58.8)

450 (47.9)

0.009

 ACEI or ARBs

120 (70.6)

610 (64.9)

0.150

 Metformin

60 (35.3)

390 (41.5)

0.130

 Sulfonylurea

40 (23.5)

280 (39.8)

0.097

 Thiazolidinedione

0 (0)

70 (7.4)

< 0.001

 Insulin

80 (47.0)

620 (66.0)

< 0.001

Liver decompensation

–

675 (71.8)

Â